The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | cfDNA WGS versus plasma proteomics for minimally invasive MRD assessment in myeloma
Dory Abelman, PhD, Dana-Farber Cancer Institute, Boston, MA, provides insight into a study comparing two minimally invasive technologies, cell-free DNA whole-genome sequencing (cfDNA WGS) and plasma proteomics using EasyM, for measurable residual disease (MRD) detection in multiple myeloma (MM). Dr Abelman highlights that both methods may provide utility for identifying patients at risk of progression and those who require early intervention, while sparing patients from frequent invasive bone marrow aspirates. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
